FBI-1在乳腺癌新辅化疗前后表达的临床意义
Analyses of the Expression of FBI-1 in Breast Cancer Pre-and Pro-neoadjuvant Chemotherapy
目的 探讨人类免疫缺陷病毒短转录诱导物连接因子1(FBI-1)在乳腺癌患者新辅化疗前后的表达情况与疗效的关系.方法 收集广西医科大学附属肿瘤医院乳腺外科2010年1月—2014年12月50例行新辅助化疗后再接受手术治疗的女性乳腺癌病例(中位年龄44岁),用免疫组织化学染色法检测新辅助治疗前后乳腺癌组织中FBI-1的表达,比较化疗前后FBI-1的表达率,并分析其与一般临床特征、病理特征及临床病理疗效的关系.结果 (1)新辅助化疗前,乳腺癌组织中FBI-1的高表达率为70%(35/50),FBI-1的表达与临床分期、淋巴结转移状态有关(P<0.05),而与患者年龄、雌激素受体(ER)、孕激素受体(PR)、Ki-67、人表皮生长因子受体(Her)-2状态无关(P>0.05);(2)无论从临床疗效评估(86.7%与51.4%,P=0.019)或是病理疗效评估(80.0%与28.6%,P=0.001),新辅助化疗前FBI-1低表达组化疗疗效均显著优于高表达组;(3)新辅助化疗显著降低FBI-1的高表达率(70.0%与38.0%,P=0.004),22例患者(62.9%)FBI-1由高表达转为低表达;(4)临床疗效显著组FBI-1表达下降较临床疗效非显著组明显(77.4%与26.3%,P=0.001),病理缓解显著组FBI-1表达下降较病理缓解非显著组明显(72.7%与39.3%,P=0.024),FBI-1表达是否下降与新辅助化疗的临床疗效(r=0.440,P<0.01)、病理疗效(r=0.491,P<0.05)有相关性.结论 接受新辅助化疗的乳腺癌患者中,FBI-1高表达与临床分期、淋巴结转移具有相关性;新辅助化疗能够显著降低乳腺癌组织中FBI-1的表达水平;FBI-1的高表达可能预示对化疗药物的耐药性,并对乳腺癌患者新辅助化疗的疗效具有预测价值.
更多Objective To investigate the expression of factor that binds to inducer of short transcripts-1 of HIV ( FBI-1 ) in breast cancer pre-and pro-neoadjuvant chemotherapy and explore the relationship between FBI-1 expression and treatment efficacy .Methods We collected 50 patients with breast cancer who received neoadjuvant chemotherapy before operation in the Affiliated Tumor Hospital of Guangxi Medical University from January , 2010 to December, 2014.The expression of FBI-1 in breast cancer tissues pre-and pro-neoadjuvant chemotherapy was detected by immunohistochemical staining .We compared the level of FBI-1 expression pre-and pro-neoadjuvant chemotherapy , and tried to explore its relationship with patient and tumor characteristics and treatment efficacy . Results ( 1 ) The rate of upregulated expression of FBI-1 in breast cancer tissues was 70%(35/50).The upregulated expression of FBI-1 was related to the higher clinical stage and trend of lymph node metastasis ( P<0.05 ) , whereas not related to the age and expression of ER , PR, Ki-67, and Her-2(P>0.05);(2) the setting of FBI-1 lower expression pre-neoadjuvant chemotherapy had superior treatment outcome than the high expression setting based on either clinical assessment (86.7% vs 51.4%,P=0.027) or pathological assessment (80.0% vs 28.6%,P=0.001 ); ( 3 ) the rate of upregulated FBI-1 expression was significantly decreased post-neoadjuvant chemotherapy ( 70.0% vs 38.0%, P=0.004 ) , with FBI-1 expression of 22 patients downregulated (62.9%);(4) the expression of FBI-1 in responded setting was significantly decreased than that in the non-responded setting based on either clinical ( 77.4% vs 26.3%, P=0.001 ) or pathological (72.7%vs 39.3%,P=0.024) assessment.The downregulation of FBI-1 was correlated to either clinical efficacy (r=0.440,P<0.01) or pathological efficacy (r=0.491,P<0.05) of neoadjuvant chemotherapy. Conclusion In breast cancer patients receiving neoadjuvant chemotherapy , the upregulated expression of FBI-1 in breast cancer lesion is associated with clinical stage and lymph node metastasis .The neoadjuvant chemotherapy can significantly reduce the expression of FBI-1.The upregulated expression of FBI-1 may be predictive of resistance to chemotherapeutic drugs , and has predictive value for the efficacy of neoadjuvant chemotherapy in breast cancer patients .
More- 浏览:164
- 被引:4
- 下载:76
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文